Galidesivir hydrochloride is primarily investigated for its antiviral properties, particularly against RNA viruses. It has shown potential in treating infections caused by viruses such as Ebola, Marburg, and Zika. The compound works by inhibiting viral RNA polymerase, thereby preventing viral replication. Clinical studies have explored its efficacy in reducing viral load and improving patient outcomes in severe viral infections. Additionally, it has been considered for use in combating emerging viral threats due to its broad-spectrum antiviral activity. Research continues to evaluate its safety, effectiveness, and potential as a therapeutic option in both human and veterinary medicine.